PROCEDIMIENTO PARA PREDECIR LA EFICACIA DE LA INMUNOTERAPIA PARA CANCER EN UN INDIVIDUO, CON RESPECTO AL BENEFICIO CLINICO, QUE COMPRENDE PROVEER UNA MUESTRA DE SANGRE DE DICHO INDIVIDUO, DETERMINAR EL NUMERO DE LINFOCITOS Y NEUTROFILOS EN LA SANGRE,

摘要

The invention relates to a method for predicting the efficacy of a cancer immunotherapy of an individual with respect to clinical benefit, which comprises the following steps:
- providing a blood sample of said individual,
- (a1) determining the number of lymphocytes in the blood of said individual, and/or
- (a2) determining the number of neutrophils in the blood of said individual, and
- (b1) identifying the individual as having a predictive clinical benefit from the immunotherapy, if the number of lymphocytes is below or equal to a lymphocyte baseline level of 1,4 to 1,8 x 10 9 per liter blood, especially below or equal to 1,6 x 10 9 per liter blood; or
- (b2) identifying the individual as having a predictive clinical benefit from the immunotherapy, if the number of neutrophils is below or equal to a neutrophil baseline level of from 4,0 to 6,0 x 10 9 per liter blood, especially below or equal to 5,0 x 10 9 neutrophils per liter blood; or
- (b3) identifying the individual as not having a predictive clinical benefit, if the number of lymphocytes is above a lymphocyte baseline level of 1,4 to 1,8 x 10 9 per liter blood, especially above 1,6 x 10 9 per liter blood and the number of neutrophils is above a neutrophil baseline level of from 4,0 to 6,0 x 10 9 per liter blood, especially above 5,0 x 10 9 neutrophils per liter blood.